An Ode to Remembrance on Prescribed Harm Day
SHARE | PRINT | EMAIL
There are many more hidden Vioxxes in our medicine cabinets, which exist due to systemic flaws in drug regulation that allows dangerous medications to flood the... Read more.
The Great Menopause Grift
SHARE | PRINT | EMAIL
The grift goes wide and deep. Many influencers and physician-educators have financial ties through sponsored content or brand partnerships, sometimes pushing lines... Read more.
Cycles of Enthusiasm, Reversal, and Revival in Medical Practice
SHARE | PRINT | EMAIL
It’s hard to generalize, but when reversals are based on better quality evidence, we should presume they’re in the public interest. However, when they are based... Read more.
Malflusiva and the Wheeking Guinea Pigs
SHARE | PRINT | EMAIL
The most infuriating part of the VRBPAC meeting was that the members actually acknowledged and discussed some of these concerns, but instead of postponing its recommendation,... Read more.
The Trouble with Cancer Screening in Healthy Adults
SHARE | PRINT | EMAIL
We framed screening as prevention; instead, it has become a factory of medicalization, anxiety, and expense. If medicine’s moral compass is to be preserved, we... Read more.
Less Is More in Medicine
SHARE | PRINT | EMAIL
We need to be asking questions about whether sending more of our collective wealth towards our healthcare system is producing good returns. We might expect that... Read more.
The Biggest Breast Cancer Advance in the Last Twenty Years
SHARE | PRINT | EMAIL
Some clinicians and public-health researchers would argue that the media narrative minimizes known and proven downsides of these drugs, often trivializing or ignoring... Read more.
The Ozempic Paradox
SHARE | PRINT | EMAIL
The same week that our drug regulator, Health Canada, approved the first generic version of semaglutide—the active ingredient in weight-loss drug Ozempic—a major... Read more.
Let’s Save Our Doctors’ Time for Sick People
SHARE | PRINT | EMAIL
What would a smarter approach look like? Our health systems need to create clear, evidence-based thresholds for when to recommend screening or primary prevention... Read more.
You Can’t Unsee This
SHARE | PRINT | EMAIL
This latest dispatch from the world of pharmaceutical safety comes from that drug class that is a gift that keeps on giving, the blockbuster weight-loss drugs known... Read more.
What Does the Fifth Doctor Think about Ozempic?
SHARE | PRINT | EMAIL
This is a slightly shortened version of a New York Times article where Katrin Bennhold interviews Dani Blum of the Times’ “Well Team” about Ozempic and GLP-1... Read more.
Book Review of No More Tears: the Dark Secrets of Johnson & Johnson
SHARE | PRINT | EMAIL
Johnson & Johnson’s reputation comes under fire in Gardiner Harris’s new book No More Tears: The Dark Secrets of Johnson & Johnson. He delivers an impressively-researched... Read more.